GO:1904150 negative regulation of microglial cell mediated cytotoxicity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904150 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of microglial cell mediated cytotoxicity.
• Microglial cytotoxicity is a double-edged sword: it clears damaged cells but can also drive neurodegeneration when unchecked.
• Key regulatory nodes include NF-kB, NLRC5, TLR4/MyD88, Piezo1, and Nrf2/HO-1 signaling pathways.
• Pharmacological and genetic inhibition of these pathways reduces microglial-mediated neuronal damage in models of HIV-associated neurocognitive disorders, multiple sclerosis, and stroke.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of candidate genes in this process.
• Targeting negative regulation of microglial cytotoxicity is a promising therapeutic strategy for neuroinflammatory and neurodegenerative diseases.
Description
Microglial cells are the resident macrophages of the central nervous system and play critical roles in immune surveillance, synaptic pruning, and response to injury. However, when chronically activated, microglia can mediate cytotoxicity against neurons and other glial cells, contributing to neuroinflammatory and neurodegenerative pathologies. The Gene Ontology term GO:1904150, negative regulation of microglial cell mediated cytotoxicity, captures the biological processes that restrain this damaging potential. Understanding these regulatory mechanisms is essential for developing therapies that preserve beneficial microglial functions while preventing collateral neuronal damage. This article synthesizes current knowledge on the molecular players, signaling pathways, and experimental models used to study negative regulation of microglial cell mediated cytotoxicity, based on authoritative QuickGO annotation and published literature.
negative regulation of microglial cell mediated cytotoxicity At A Glance
| GO ID | GO:1904150 |
|---|---|
| GO term | negative regulation of microglial cell mediated cytotoxicity |
| Ontology | biological_process |
| Synonym | down regulation of microglial cell mediated cytotoxicity; down-regulation of microglial cell mediated cytotoxicity; downregulation of microglial cell mediated cytotoxicity; inhibition of microglial cell mediated cytotoxicity |
| Major function | Suppression of microglial cytotoxic activity against neurons and other cells |
| Related processes | Neuroinflammation, microglial activation, cytokine production, oxidative stress |
| Key signaling pathways | TLR4/MyD88/NF-kB, Nrf2/HO-1, NLRC5-NF-kB, Piezo1, GSDMD-mediated pyroptosis |
| Disease relevance | HIV-associated neurocognitive disorders, multiple sclerosis, stroke, neurodegeneration |
What Is GO:1904150?
GO:1904150 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of microglial cell mediated cytotoxicity. In other words, it encompasses all molecular and cellular events that dampen the ability of microglia to kill or damage other cells, particularly neurons. This regulation can occur through soluble factors, cell-cell contact, or intracellular signaling that suppresses cytotoxic effector mechanisms such as release of pro-inflammatory cytokines, nitric oxide, or pyroptotic mediators.
Why Is negative regulation of microglial cell mediated cytotoxicity Important in Cell Biology?
Negative regulation of microglial cell mediated cytotoxicity is critical for maintaining central nervous system homeostasis and preventing excessive neuronal damage during neuroinflammation. Dysregulation of this process is implicated in the pathogenesis of several neurological disorders, including HIV-associated neurocognitive disorders, multiple sclerosis, and stroke. Therefore, identifying the molecular brakes that control microglial cytotoxicity is essential for developing targeted therapies that mitigate neuroinflammation without compromising beneficial immune functions.
• Prevents collateral neuronal damage during acute and chronic neuroinflammation.
• Modulates the balance between protective and pathogenic microglial activities.
• Involved in the pathogenesis of HIV-associated neurocognitive disorders via Tat-mediated microglial inflammation.
• Key to limiting demyelination in multiple sclerosis models through Piezo1 inhibition.
• Regulates oxidative stress and nitric oxide production in activated microglia.
• Controls inflammatory cell death pathways such as pyroptosis via GSDMD.
• Potential therapeutic target for stroke and other acute brain injuries.
• Influenced by endogenous factors like 25-hydroxyvitamin D3 and neuronal glycolipids.
• Provides a mechanistic basis for anti-inflammatory drug development.
• Essential for understanding microglial heterogeneity in health and disease.
What Happens During negative regulation of microglial cell mediated cytotoxicity?
Initiation of Microglial Activation
In simple terms: Microglia get activated by danger signals, which can lead to harmful behavior if not controlled.
Microglial cells become activated in response to inflammatory stimuli such as lipopolysaccharide (LPS), HIV-1 Tat protein, or damage-associated molecular patterns. This activation involves Toll-like receptor 4 (TLR4) and its adaptor MyD88, leading to downstream signaling that can initiate cytotoxic programs. The initial activation step is necessary for host defense but must be tightly regulated to prevent excessive damage.
Suppression of Pro-inflammatory Signaling
In simple terms: Certain pathways act as brakes on the inflammation caused by activated microglia.
Negative regulation of microglial cytotoxicity often involves inhibition of the NF-kB pathway. For example, Nobiletin, a natural compound, reduces LPS-induced neuroinflammation by modulating TLR4/MyD88/NF-kB and activating Nrf2/HO-1 signaling in human microglial HMC3 cells. Similarly, the miRNA-34a-NLRC5-NF-kB axis has been shown to regulate HIV-1 Tat-mediated microglial inflammation, where NLRC5 acts as a negative regulator of NF-kB. These pathways represent endogenous mechanisms that dampen cytotoxic responses.
Inhibition of Cytotoxic Effectors
In simple terms: The actual killing tools of microglia, like nitric oxide and pyroptotic proteins, are turned down.
Microglial cytotoxicity is mediated by effectors such as nitric oxide (NO), reactive oxygen species, and pyroptosis-related proteins like GSDMD. Negative regulation can occur by reducing NO production, as shown with 25-hydroxyvitamin D3 treatment in activated microglia. Additionally, inhibition of GSDMD-mediated pyroptosis by E. globulus leaf essential oil alleviates neuroinflammation in experimental stroke mice. These examples illustrate direct suppression of cytotoxic effector mechanisms.
Modulation by Neuronal and Environmental Cues
In simple terms: Neurons and other cells send signals that tell microglia to calm down.
Neuronal glycolipids have been shown to negatively regulate glial cell division during development and after lesions, suggesting that neuronal-derived factors can restrain microglial activity. Additionally, inhibition of the mechanosensitive ion channel Piezo1 attenuates demyelination in the central nervous system, partly by modulating microglial responses. These findings highlight the role of microenvironmental cues in negative regulation of microglial cytotoxicity.
Resolution and Return to Homeostasis
In simple terms: After the threat is gone, microglia return to a resting state to avoid ongoing damage.
Successful negative regulation leads to resolution of inflammation and restoration of microglial homeostatic functions. This involves downregulation of pro-inflammatory cytokines, upregulation of anti-inflammatory mediators, and restoration of phagocytic capacity without cytotoxicity. The dual role of inflammatory stimuli in activation-induced cell death of microglial cells also suggests that self-limiting mechanisms exist to prevent persistent cytotoxicity.
Key Genes Involved in GO:1904150 negative regulation of microglial cell mediated cytotoxicity
The following genes and proteins have been implicated in the negative regulation of microglial cell mediated cytotoxicity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TLR4 | Initiates inflammatory signaling; its negative regulation dampens microglial cytotoxicity | Target for anti-inflammatory compounds like Nobiletin |
| MYD88 | Adaptor protein in TLR4 signaling; downregulation reduces NF-kB activation | Key node in LPS-induced neuroinflammation |
| NFKB1 | Transcription factor driving pro-inflammatory gene expression; inhibited by negative regulators | Central to microglial cytotoxic gene programs |
| NLRC5 | Negative regulator of NF-kB; its induction suppresses microglial inflammation | Modulated by miRNA-34a in HIV-1 Tat-mediated inflammation |
| PIEZO1 | Mechanosensitive ion channel; its inhibition reduces demyelination and microglial activation | Therapeutic target in multiple sclerosis models |
| NFE2L2 | Transcription factor activating antioxidant response; protects against oxidative stress | Mediates Nrf2/HO-1 pathway in microglia |
| HMOX1 | Antioxidant enzyme; reduces oxidative stress and inflammation | Downstream effector of Nrf2 in microglia |
| GSDMD | Mediates pyroptosis; its inhibition reduces neuroinflammation | Target of E. globulus leaf essential oil in stroke |
| CASP11 | Caspase-11 involved in non-canonical inflammasome and cell death | Implicated in activation-induced microglial cell death |
| IRF1 | Interferon regulatory factor 1; regulates apoptotic pathways in microglia | Dual role in inflammatory cell death |
| VDR | Vitamin D receptor; mediates anti-inflammatory effects of 25-hydroxyvitamin D3 | Reduces nitric oxide production in activated microglia |
| MIR34A | MicroRNA that targets NLRC5; modulates NF-kB activity | Regulates HIV-1 Tat-mediated microglial inflammation |
| P2RY12 | Purinoceptor involved in microglial motility and surveillance | Potential homeostatic marker; not directly cited in provided list |
| CX3CR1 | Fractalkine receptor; maintains microglial quiescence | Not directly cited in provided list |
| TREM2 | Involved in phagocytosis and microglial activation | Not directly cited in provided list |
| CD200R | Inhibitory receptor that dampens microglial activation | Not directly cited in provided list |
| IL10 | Anti-inflammatory cytokine; suppresses microglial cytotoxicity | Not directly cited in provided list |
| TGFB1 | Anti-inflammatory cytokine; promotes microglial quiescence | Not directly cited in provided list |
How Is negative regulation of microglial cell mediated cytotoxicity Regulated?
Negative regulation of microglial cell mediated cytotoxicity is controlled by multiple intracellular and extracellular signals. Key regulatory pathways include the TLR4/MyD88/NF-kB axis, which can be suppressed by compounds like Nobiletin and by NLRC5 induction. The Nrf2/HO-1 antioxidant pathway also plays a protective role by reducing oxidative stress. Additionally, mechanosensitive Piezo1 channels and GSDMD-mediated pyroptosis are emerging as regulatory nodes. Endogenous factors such as 25-hydroxyvitamin D3 and neuronal glycolipids further modulate microglial activity. These pathways collectively maintain microglial cytotoxicity in check.
negative regulation of microglial cell mediated cytotoxicity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NLRC5 | HIV-associated neurocognitive disorders | HIV-1 Tat-treated microglial cells with NLRC5 knockdown/overexpression |
| PIEZO1 | Multiple sclerosis / demyelination | Experimental autoimmune encephalomyelitis (EAE) mice with Piezo1 inhibitor |
| GSDMD | Ischemic stroke | Middle cerebral artery occlusion (MCAO) mice treated with E. globulus oil |
| NFE2L2 | Neuroinflammation / oxidative stress | LPS-stimulated HMC3 cells treated with Nobiletin |
| VDR | Neuroinflammation | Activated microglia treated with 25-hydroxyvitamin D3 |
HIV-Associated Neurocognitive Disorders (HAND)
HIV-1 Tat protein activates microglia and induces inflammatory responses that contribute to HAND. The miRNA-34a-NLRC5-NF-kB axis has been identified as a key regulator of Tat-mediated microglial inflammation, where NLRC5 acts as a negative regulator of NF-kB. Targeting this axis could reduce microglial cytotoxicity and alleviate HAND pathology.
Multiple Sclerosis and Demyelination
Inhibition of Piezo1 attenuates demyelination in the central nervous system, partly by modulating microglial responses. This suggests that negative regulation of microglial cytotoxicity is protective in multiple sclerosis models. Strategies to inhibit Piezo1 or enhance endogenous negative regulators may promote remyelination and reduce disease severity.
Ischemic Stroke
E. globulus leaf essential oil exhibits anti-inflammatory effects by regulating GSDMD-mediated pyroptosis, thereby alleviating neurological impairment and neuroinflammation in experimental stroke mice. This highlights the therapeutic potential of targeting pyroptosis to negatively regulate microglial cytotoxicity after stroke.
Neurodegenerative Diseases
Chronic microglial activation and cytotoxicity contribute to neurodegeneration. Negative regulators such as Nrf2/HO-1 and anti-inflammatory cytokines may protect against neuronal loss. Vitamin D3 and its receptor also reduce nitric oxide production in activated microglia, suggesting a role in neuroprotection.
From negative regulation of microglial cell mediated cytotoxicity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate microglial cytotoxicity? | CRISPR knockout of gene X in BV-2 or HMC3 microglial cells followed by LPS stimulation |
| Does a point mutation in gene Y affect its regulatory function? | CRISPR point mutation knock-in of the mutation in microglial cells |
| Does overexpression of gene Z suppress microglial cytotoxicity? | Lentiviral overexpression of gene Z in primary microglia or cell lines |
| Does a tagged version of protein W localize correctly? | CRISPR knock-in of a fluorescent tag (e.g., GFP) at the endogenous locus |
| Can a drug modulate negative regulation? | Pharmacological treatment of wild-type and knockout microglia with compounds like Nobiletin |
| What is the transcriptomic profile of regulated microglia? | RNA-seq of microglia with CRISPR perturbations |
How to Study the negative regulation of microglial cell mediated cytotoxicity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on microglial cytotoxicity | Identify negative regulators in LPS-stimulated microglia |
| RNA-seq | Transcriptional changes | Profile microglial responses to anti-inflammatory compounds |
| Proteomics | Protein expression and modifications | Discover signaling nodes in negative regulation |
| Live-cell imaging | Real-time cytotoxic activity | Assess microglia-neuron interactions |
| Flow cytometry | Cytokine production, cell death | Quantify microglial activation states |
| Western blot | Protein phosphorylation and expression | Validate NF-kB and Nrf2 pathway modulation |
| ELISA | Cytokine and nitric oxide levels | Measure inflammatory mediators |
| CRISPR knock-in | Tagged protein localization and function | Study endogenous protein dynamics |
CRISPR Screening for Regulators
Genome-wide CRISPR knockout or activation screens in microglial cell lines can identify genes whose loss or gain alters microglial cytotoxicity. For example, screening with LPS stimulation and measuring neuronal survival or inflammatory cytokines can uncover novel negative regulators.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics of microglia under conditions that induce or suppress cytotoxicity can reveal pathways and networks involved in negative regulation. Studies using Nobiletin and HIV-1 Tat have employed such approaches to identify NF-kB and Nrf2 targets.
Functional Validation with Knockout and Knock-in Models
After candidate genes are identified, CRISPR knockout and knock-in (point mutation or tagged) models are used to validate their causal role. For instance, NLRC5 knockout enhances Tat-induced NF-kB activation, confirming its negative regulatory function.
Imaging and Live-Cell Assays
Live-cell imaging of microglia-neuron co-cultures can directly assess microglial cytotoxicity and its regulation. Fluorescent reporters for calcium, ROS, or caspase activity allow real-time monitoring of negative regulatory events.
How CRISPR Can Be Used to Study GO:1904150 negative regulation of microglial cell mediated cytotoxicity
Knockout
CRISPR knockout of candidate negative regulators (e.g., NLRC5) in microglial cells can confirm their role in suppressing cytotoxicity. For example, NLRC5 knockout exacerbates HIV-1 Tat-induced NF-kB activation and inflammatory cytokine production. Knockout models are essential for loss-of-function studies.
Point Mutation
Point mutations can be introduced to dissect specific domains or phosphorylation sites required for negative regulation. For instance, mutating key residues in NLRC5 or NF-kB subunits can reveal their functional importance. CRISPR point mutation knock-in allows precise editing without altering other genomic regions.
Knock-in
Knock-in of reporter tags (e.g., GFP) or epitope tags at endogenous loci enables visualization and immunoprecipitation of negative regulators in their native context. This is particularly useful for studying proteins like Piezo1 or GSDMD.
Overexpression
Overexpression of negative regulators (e.g., NLRC5, Nrf2) via lentiviral vectors can suppress microglial cytotoxicity and protect neurons. This approach is valuable for gain-of-function studies and therapeutic target validation.
How EDITGENE Supports negative regulation of microglial cell mediated cytotoxicity Research
Researchers studying negative regulation of microglial cell mediated cytotoxicity-related genes often need to determine whether a candidate gene is causally involved in suppressing microglial cytotoxicity or is merely a bystander. EDITGENE provides comprehensive CRISPR-based services to enable such causal investigations, from knockout to precise point mutations and knock-in reporters.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of microglial cell mediated cytotoxicity research.
Frequently Asked Questions About negative regulation of microglial cell mediated cytotoxicity
What is GO:1904150?
GO:1904150 is a Gene Ontology term for any process that stops, prevents, or reduces the frequency, rate, or extent of microglial cell mediated cytotoxicity.
What genes are involved in negative regulation of microglial cell mediated cytotoxicity?
Key genes include NLRC5, TLR4, MYD88, NFKB1, PIEZO1, NFE2L2, HMOX1, GSDMD, and MIR34A, among others.
How is microglial cytotoxicity negatively regulated?
It is regulated through pathways such as TLR4/MyD88/NF-kB inhibition, Nrf2/HO-1 activation, NLRC5 induction, Piezo1 inhibition, and suppression of GSDMD-mediated pyroptosis.
What diseases are associated with dysregulation of this process?
HIV-associated neurocognitive disorders, multiple sclerosis, ischemic stroke, and neurodegenerative diseases.
What experimental models are used to study negative regulation of microglial cytotoxicity?
Common models include LPS-stimulated microglial cell lines (HMC3, BV-2), HIV-1 Tat treatment, EAE mice, and MCAO stroke models.
How can CRISPR help study this GO term?
CRISPR knockout, point mutation, knock-in, and overexpression allow causal testing of candidate genes in microglial cells.
What is the role of NLRC5 in microglial cytotoxicity?
NLRC5 acts as a negative regulator of NF-kB and suppresses HIV-1 Tat-mediated microglial inflammation.
Does vitamin D regulate microglial cytotoxicity?
Yes, 25-hydroxyvitamin D3 reduces nitric oxide production in activated microglia, indicating a negative regulatory role.
What is the role of Piezo1 in demyelination?
Inhibition of Piezo1 attenuates demyelination in the CNS, partly by modulating microglial responses.
How does GSDMD contribute to neuroinflammation?
GSDMD mediates pyroptosis; its inhibition reduces neuroinflammation and neurological impairment in stroke models.
Conclusion
Negative regulation of microglial cell mediated cytotoxicity (GO:1904150) is a vital biological process that restrains the damaging potential of activated microglia. Key molecular players such as NLRC5, Piezo1, Nrf2, and GSDMD provide promising targets for therapeutic intervention in neuroinflammatory and neurodegenerative diseases. Understanding these mechanisms through CRISPR-based models will accelerate the development of precision therapies.
References
- 1. Tizard I et al.. 2016. The pathogenesis of bornaviral diseases in mammals.. Anim Health Res Rev 17(2):92-109 PMID: 27212192
- 2. Kritika et al.. 2025. Nobiletin Reduces LPS-Induced Neuroinflammation through TLR4/MyD88/NF-κB and Oxidative Stress via Nrf2/HO-1 Signaling in Human Microglial HMC3 Cells.. Mol Neurobiol 63(1):103 PMID: 41261295
- 3. Periyasamy P et al.. 2019. HIV-1 Tat-mediated microglial inflammation involves a novel miRNA-34a-NLRC5-NFκB signaling axis.. Brain Behav Immun 80:227-237 PMID: 30872089
- 4. Velasco-Estevez M et al.. 2020. Inhibition of Piezo1 attenuates demyelination in the central nervous system.. Glia 68(2):356-375 PMID: 31596529
- 5. Hur J et al.. 2014. Regulatory Effect of 25-hydroxyvitamin D3 on Nitric Oxide Production in Activated Microglia.. Korean J Physiol Pharmacol 18(5):397-402 PMID: 25352759
- 6. Lee J et al.. 2001. Dual role of inflammatory stimuli in activation-induced cell death of mouse microglial cells. Initiation of two separate apoptotic pathways via induction of interferon regulatory factor-1 and caspase-11.. J Biol Chem 276(35):32956-65 PMID: 11402054
- 7. Nieto-Sampedro M et al.. 2017. [Neuronal glycolipids regulate glial cell division negatively during development and following a lesion].. Rev Neurol 64(12):549-567 PMID: 28608355
- 8. Wang D et al.. 2024. E. globulus leaf EO exhibits anti-inflammatory effects by regulating GSDMD-mediated pyroptosis, thereby alleviating neurological impairment and neuroinflammation in experimental stroke mice.. J Ethnopharmacol 319(Pt 3):117367 PMID: 38380569
